A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial

Gampenrieder, S; Angela, R; Rinnerthaler, G; Hackl, H; Steiner, M; Pulverer, W; Weinhaeusel, A; Klinglmayr, E; Karl, T; Ilic, S; Hufnagl, C; Hauser-Kronberger, C; Egle, A; Greil, R

View this publication in the PUBMED database